SCHEMBL3515769

SCHEMBL3515769

O=c1c(-c2ccccc2)c(O)c2cc(-c3ccc4ccccc4c3)cnc2n1O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FTO Q9C0B1 1/20 0.40
EGLN1 Q9GZT9 1/20 0.40
EGLN3 Q9H6Z9 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
SGK1 O00141 3/20 0.39
KMT2A Q03164 2/20 0.38
LMNA P02545 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD17B1 P14061 1/20 0.38
HSD17B2 P37059 1/20 0.38
KDM4E B2RXH2 2/20 0.37
RCE1 Q9Y256 1/20 0.37
ACMSD Q8TDX5 1/20 0.36
GSK3A P49840 1/20 0.36
GSK3B P49841 1/20 0.36
PIK3CD O00329 1/20 0.36
PIK3CA P42336 1/20 0.36
PIK3CB P42338 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3516992 0.88 COMT (0.43) HDAC4HDAC2HDAC8KMT2ALMNA
SCHEMBL3515126 0.81 AVPR1B (0.40) SGK1KMT2ALMNASMN1; SMN2KDM4E
SCHEMBL3517548 0.79 KMT2A (0.44) KMT2ALMNASMN1; SMN2KDM4ERCE1
SCHEMBL13435228 0.79 KDM4E (0.47) KMT2ALMNASMN1; SMN2KDM4ERCE1
SCHEMBL3515715 0.79 KMT2A (0.42) KMT2ALMNASMN1; SMN2KDM4ERCE1
SCHEMBL3519936 0.76 IP6K1 (0.41) KMT2ALMNASMN1; SMN2KDM4ERCE1
SCHEMBL3517390 0.76 KDM4E (0.41) KMT2ALMNASMN1; SMN2KDM4ERCE1
SCHEMBL3518351 0.76 KDM4E (0.47) KMT2ALMNASMN1; SMN2KDM4ERCE1
SCHEMBL13461594 0.75 COMT (0.48) HDAC4HDAC2HDAC8KMT2ALMNA
SCHEMBL3515088 0.74 KMT2A (0.34) EGLN1KMT2ALMNASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100056516-A1 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS MERCK SHARP & DOHME CORP. 2010-03-04 US disclosed
US-20100056516-A1 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS MERCK SHARP & DOHME CORP. 2010-03-04 US disclosed
US-20100056516-A1 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS MERCK SHARP & DOHME CORP. 2010-03-04 US disclosed
WO-2008010964-A1 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS MERCK & CO., INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056516-A1 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS RNASEH1, RNASE1, RNASEL FTO 3677/4885EGLN1 1767/4885EGLN3 1825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.